Overview

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Status:
Completed

Trial end date:
2009-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung cancer receiving gemcitabine and platinum.

Phase:

Phase 2

Details

Lead Sponsor:

Amgen

Treatments:

Carboplatin
Cisplatin
Gemcitabine